- Home
- NRXS vs NERV Comparison
NRXS vs NERV Comparison
Compare NRXS & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- NERV
- Stock Information
- Founded
- NRXS 2011
- NERV 2007
- Country
- NRXS United States
- NERV United States
- Employees
- NRXS N/A
- NERV N/A
- Industry
- NRXS
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- NERV Health Care
- Exchange
- NRXS Nasdaq
- NERV Nasdaq
- Market Cap
- NRXS 13.0M
- NERV 12.0M
- IPO Year
- NRXS 2023
- NERV 2014
- Fundamental
- Price
- NRXS $2.77
- NERV $2.13
- Analyst Decision
- NRXS Strong Buy
- NERV Hold
- Analyst Count
- NRXS 1
- NERV 1
- Target Price
- NRXS $7.00
- NERV $5.00
- AVG Volume (30 Days)
- NRXS 85.1K
- NERV 20.2K
- Earning Date
- NRXS 08-08-2025
- NERV 08-05-2025
- Dividend Yield
- NRXS N/A
- NERV N/A
- EPS Growth
- NRXS N/A
- NERV N/A
- EPS
- NRXS N/A
- NERV 0.83
- Revenue
- NRXS $2,934,945.00
- NERV N/A
- Revenue This Year
- NRXS $138,883.78
- NERV N/A
- Revenue Next Year
- NRXS $118.59
- NERV N/A
- P/E Ratio
- NRXS N/A
- NERV $2.61
- Revenue Growth
- NRXS 27.52
- NERV N/A
- 52 Week Low
- NRXS $1.33
- NERV $1.15
- 52 Week High
- NRXS $6.20
- NERV $3.30
- Technical
- Relative Strength Index (RSI)
- NRXS 57.38
- NERV 66.09
- Support Level
- NRXS $2.55
- NERV $1.94
- Resistance Level
- NRXS $2.92
- NERV $2.32
- Average True Range (ATR)
- NRXS 0.17
- NERV 0.15
- MACD
- NRXS 0.03
- NERV 0.03
- Stochastic Oscillator
- NRXS 78.26
- NERV 73.38
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.